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Abstract 
 
Introduction: Type 2 diabetes mellitus (T2DM) is a multifactorial disease with a strong genetic 
component interacting with environmental factors. Many genes have been significantly 
associated with developing type 2 diabetes mellitus. Most of these genes have been linked to 
beta-cell dysfunction, impaired glucose homeostasis and insulin secretion. Transcription factor-
7–like 2 (TCF7L2) gene has been found as an unexpected suspect for type 2 diabetes.  The 
strongest and most commonly associated alleles of the TCF7L2 gene in T2DM in many countries 
are rs7903146 and rs12255372. 
Aim: The aim of this study was to evaluate the association between TCF7L2 gene in T2DM 
among Palestinian people. Two SNP’s rs7903146C/T, rs12255372G/T alleles in the TCF7L2 
gene were investigated in diabetic patients and control groups.  
Methods: This is a case control study. A total of 326 participants were included in this study; 
249 participants with T2DM and 77 normal glycemic controls. RFLP PCR was performed using 
two restriction enzymes RsaI and BseGI to identify the presence of the two specific mutations in 
the alleles of the TCF7L2 gene among the study population. Allele specific PCR was also 
performed to substitute for DNA sequencing on one hand and to genotype the TCF7L2 gene as 
homo or heterozygous. We used SPSS v.21 to compare the results obtained of the case and 
control groups. 
X 
 
 
 
Results: There was a strong association between the two SNP’s rs7903146C/T, rs12255372G/T 
alleles and T2DM. Both alleles have statistically significant association with the disease.  Each 
of the two alleles had stronger association with T2DM when tested alone than when both alleles 
were combined. We observed that several normal participants carried the SNP in one or both 
alleles. This indicates the possibility of future development of diabetes. 
Conclusion: TCF7L2gene is strongly associated with T2DM. This important finding can be 
utilized in screening the population at risk of developing diabetes. Furthermore, genetic testing 
can also be applied to the normal population to determine who can be prone to develop diabetes 
in the future. 
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 الخلاصة
 
) هو مرض متعدد العوامل مع عنصر وراثي قوي التفاعل مع العوامل البيئية. MD2Tالثاني من داء السكري ( النوع: المقدمة
النوع الثاني من داء السكري. وقد تم ربط معظم هذه الجينات إلى  وهناك العديد من الجينات المرتبطة بشكل كبير مع تطور
) باعتباره المشتبه به 2L7FCTضعف خلايا بيتا، وضعف توازن الجلوكوز وإفراز الأنسولين.  حيث تم العثور على الجين (
     في الجين بطة بالأليلات غير المتوقع لمرض السكري من النوع الثاني. وان الجينات الأقوى والأكثر شيوعا منها هي المرت
 .27355221srو 6413097srفي العديد من البلدان هي  TMD2في 2L7FCT
بين الشعب الفلسطيني.  وقد تم التحقق من  MD2Tفي 2L7FCTكان الهدف من هذه الدراسة هو تقييم العلاقة بين  لقد :الهدف
في مرضى السكري وغير المرضى / G27355221sr T، T/C6413097srمنها2L7FCT في الجينPNSاثنين من
 (الطبيعيين).
 
مشاركا من  242مشاركا في هذه الدراسة؛  326. تم تضمين ما مجموعه yduts lortnoc esac: هذه دراسة من نوع الطريقة
باستخدام اثنين من  PLFR- RCPمن غير المرضى (نسبة سكر لديهم طبيعية في الدم). تم إجراء  77و MD2Tالمرضى 
بين المشتركين في الدراسة. تم  2L7FCTلتحديد وجود هذه الطفرات في الآليات من الجينات  1GesBو 1asRات الانزيم
) أيضا على ان تكون بديلا عن تسلسل الحمض النووي من جهة، وإلى التركيب RCP cificepS elellAمحددة (RCPإجراء 
) لمقارنة النتائج التي تم  12.V SSPS(الاحصاء رنامج كمتجانس أو غير متجانس. لقد استعمل ب 2L7FCTالوراثي للجين 
 الحصول عليها بين الحالة قيد الدراسة ومجموعات المراقبة.
. كلا الأليلات )MD2Tوتطور( ( T / G27355221sr، T/C6413097srكان هناك علاقة قوية بين الطفرتين  النتائج:
 السكري ن الأليلات الاثنتين رابطة أقوى مع النوع الثاني منلديها ارتباط ذي دلالة إحصائية مع المرض. وأظهر كل م
) عند اختباره وحده مما كانت عليه عندما تم الجمع بين كل من الأليلات. وقد لاحظنا أن العديد من المشاركين غير MD2T(
قبلي لمرض السكري من في واحد اوفي كلا الأليلات التي اختبرت. وهذا يدل على إمكانية التطور المست PNSالمرضى حملوا
 iiX قبلهم.
 
 
 المهم الاكتشاف هذا استخدام ويمكن ))MD2Tالسكري من الثاني النوع مع قويا ارتباطا يرتبط  2L7FCT الجين: الخلاصة
 الجينية الاختبارات تطبق أن أيضا يمكن ذلك، على وعلاوة. السكري بمرض للإصابة للخطر المعرضين السكان فحص في
 .المستقبل في السكري مرض لتطوير عرضة منهم الذين من لتحديد العاديين للسكان
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Chapter 1 
Introduction 
1.1 Early history of diabetes: 
Diabetes mellitus is the most commonly encountered endocrine disorder worldwide (1). The 
history of diabetes has its beginnings in antiquity (Asia Minor, China, Egypt, and India). The 
ancient Egyptian civilization described diabetes as the passing of large quantities of honey-sweet 
urine, and was documented in the Ebers Papyrus (dating back to 1500 BC and discovered by the 
Egyptologist Georg Ebers in Thebes in 1872 (2, 3). 
 
In the 2nd century AD, Aretaeus of Cappadocia used the term "diabetes" from the Greek word 
for "siphon" or "pass through" (4) .In the tenth century AD, Ibn Sina  described the disease in his 
book Al-Qanoon and mentioned gangrene and collapse of sexual function as complications of 
the disease. In seventeenth century in England, Thomas Willis (1621-1675), indicated that the 
sweet taste of urine could be used by physician for the diagnosis of the disease. In 1766 Mathew 
Dobson proved that the sweet taste of urine in diabetics was due to sugar (5). 
 
Paul Langerhans in 1869 discovered the islets of cells in pancreatic tissue and were later given 
his name "islet of Langerhans". Von Mering (1849-1908) and Oscar Minkowski (1858-1931) 
 hyperglycemia with ketoacidosis (mainly presents in type 1 diabetes) or the nonketotic 
hyperosmolar syndrome (it occurs more often in people with type 2, blood sugar levels rise,   
blood becomes thick and the body tries to get rid of the excess sugar by passing it into the urine )   
(9). 
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Classification of diabetes: 
  The first widely accepted classification of diabetes mellitus was published by WHO in 1980 (10) 
and then modified in 1985 (11). In 1980 there were two major classes of diabetes mellitus,   
insulin-dependent diabetes mellitus (IDDM or Type 1), and non-insulin-dependent diabetes 
mellitus (NIDDM or Type 2). In 1985,   the terms Type 1 and Type 2 were omitted, but the 
classes IDDM and NIDDM were retained. In both the 1980 and 1985 reports other classes of 
diabetes were included such as Impaired Glucose Tolerance (IGT) and Gestational Diabetes 
Mellitus (GDM). These were reflected in the subsequent International Nomenclature of Diseases 
(IND) in 1991, and the tenth revision of the International Classification of Diseases (ICD-10) in 
1992. The 1985 classification was widely accepted and used internationally. It represented a 
compromise between clinical and etiological classification, which allowed clinically useful 
classification of individual subjects and patients when the specific etiology was unknown. The 
recommended classification included staging of diabetes mellitus based on clinical descriptive 
criteria and a complementary etiological classification. The revised classification of WHO 
encompasses both clinical stages and etiological types of diabetes mellitus and other categories 
of hyperglycemia. 
The clinical staging reflects that diabetes, regardless of its etiology, progresses through several 
clinical stages during its natural course. Moreover, individual subjects may move from stage to 
stage in either direction. People who have, or who are developing, diabetes mellitus can be 
categorized by a stage according to the clinical characteristics, even in the absence of 
information concerning the underlying etiology. The classification by etiological type results 
from improved understanding of the causes of diabetes mellitus (12). 
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The classification of diabetes includes both clinical and etiological causes are divided into four 
classes :(13) 
 A Type1diabetes (IDDM), the disease tends to occur in childhood, adolescence or early 
adulthood (before age 30) but it may have its clinical onset at any age. It accounts for 
only 5–10% of the cases; it results from cellular-mediated autoimmune destruction of the-
cells of the pancreas (usually leading to absolute insulin deficiency). Markers of the 
immune destruction of the-cell include islet cell autoantibodies, autoantibodies to insulin, 
autoantibodies to glutamic acid decarboxylase (GAD65), and autoantibodies to the 
tyrosine phosphatasesIA-2 and IA-2. In addition, the disease has strong HLA 
associations, with linkage to the DQA and DQB genes, and it is influenced by the DRB 
genes, when the etiology of some forms of Type1 diabetes is not recognized, it is referred 
to as idiopathic diabetes (14). 
 
 B Type 2 diabetes (NIDDM, type II or adult-onset) is the most common form of DM, it 
accounts for 90–95% of cases, it is characterized by hyperglycemia, insulin resistance, 
and relative insulin deficiency rather than absolute insulin deficiency. In Type 2 diabetes, 
the pancreatic β cells become progressively less able to secrete sufficient insulin to 
maintain normal carbohydrate and lipid homeostasis (15).It is highly associated with 
family history of diabetes, older age, obesity and lack of exercise (16). The etiology of 
type 2 diabetes mellitus is multifactorial; it may result from interaction between genetic, 
environmental and behavioral risk factors (17). 
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 C Other specific types of diabetes: (<5% of all diagnosed cases): due to other causes 
such as: 
• Genetic defect in beta cells. 
• Insulin resistance genetically determined. 
• Diseases of the exocrine pancreas,(Such as cystic fibrosis) 
• Hormonal defects. 
• Chemicals or drugs (such as in the treatment of HIV/AIDS or after organ 
transplantation) (18). 
 D Gestational diabetes mellitus (GDM), this type is diagnosed during pregnancy 
mainly between 24 and 28 weeks of pregnancy, it occurs in 18 %of pregnancies. Women 
with a history of GDM have a high risk to develop diabetes, should be periodically 
maintained and tested (19). 
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1.3. Type 2 diabetes (non-insulin dependent DM- NIDDM, type II or adult-
onset) 
Type 2 diabetes will certainly be one of the major diseases of the 21st century (20).It was first 
described as a component of the metabolic syndrome in 1988 and the most common form of 
diabetes mellitus, which accounts for 90% of diabetic cases(21). Since Type 2 diabetes mellitus 
usually develops after the age of 40(although it is increasingly found in younger people), the 
disease is called “adult onset type diabetes mellitus”. 
 
NIDDM is characterized by hyperglycemia due to multiple defects in both insulin action and 
insulin secretion. Although many type 2 diabetes mellitus patients have a basal 
hyperinsulinaemia, rises in plasma glucose have a characteristically reduced stimulatory effect 
on insulin secretion. Insulin resistant the cells are unable to bind and internalize glucose.  Insulin 
resistance indicates that cells are either malnourished or starved as sugar levels elevated in the 
blood. In response, the pancreas compensates for this by secreting more insulin in order to lower 
glucose levels. With time, beta cells may become completely damaged resulting in insulin 
insufficiency, eventually no insulin is produced, and a person with type 2 diabetes needs insulin 
injections for survival (22). Type 2 diabetes mellitus patients are often treated by diet or with oral 
hypoglycemic drugs, but many will eventually need exogenous insulin to reduce the levels of 
hyperglycemia (23).Initially, the disease is asymptomatic resulting in a large percentage of the 
patients not seeking early medical attention, thus 30-85% of cases of type 2 diabetes remain 
undiagnosed. At the time of eventual diagnosis, approximately 20% of patients will already have 
complications of the disease (24). 
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1.4 Discovery of Type 2 Diabetes: 
 
  The remarkable success of using insulin to treat diabetes led to the notion that the disease was 
caused by lack of insulin. Observations by Roger Hinsworth in 1935 resulted in the recognition 
of two different types of diabetes. Himsworth experiments in both animals and people concluded 
that the body’s use of sugar depends on the availability of and the sensitivity of the cells to 
insulin.  By giving diabetic patients sugar and insulin simultaneously, Himsworth determined the 
actual insulin effect on the sugar.  
 These experiments showed that there are two types of diabetes: Type 1 and Type 2. People with 
type 1 diabetes were sensitive to insulin and had a history of suddenly developing the disease at 
young age; those with type 2 diabetes were relatively insensitive to insulin and tended to 
gradually develop a milder form of the disease at middle age or older. Years later, other 
researchers confirmed Himsworth’s findings with more sophisticated techniques. In the 50s, the 
work of a nuclear physicist and an internal medicine physician on diabetes research and 
treatment earned them the Nobel Prize. In the 1950s, Himsworth’s notion that type 2 diabetes 
involved reduced sensitivity to insulin was not yet well accepted by the biomedical community, 
another researcher, Arthur Mirsky, explanation for adult-onset diabetes to be due to rapid 
enzymatic digestion of insulin. Rosalyn Yalow and Solomon Berson, researchers at New York’s 
Veterans Administration Hospital, set out to test this hypothesis. They gave radioactively labeled 
insulin to people with and without diabetes. According to Mirsky’s theory, the insulin given to 
those with diabetes should have disappeared more quickly than that given to normal individuals. 
Yalow and Berson found that it disappeared more slowly. 
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The slower rate of disappearance was due to an immune response against the radiolabeled insulin 
used in the experiments.  
Radioimmunoassay was used to measure minute quantities of hormones (Pico / ml) of blood and 
other compounds circulating through the bloodstream. In 1960s, Yalow and Berson used the 
technique to measure and compare the insulin response to sugar in patients with type 2 diabetes 
and normal controls. They found that people with type 2 diabetes often generated more insulin 
than the normal controls.  Other researchers discovered that although people in the early stages 
of type 2 diabetes produce more than the normal amounts of insulin, over time their insulin 
levels declines below that seen in normal individuals and their diabetes becomes severe. The 
outcome of these findings was a new hypothesis indicating that to compensate for their lack of 
sensitivity to insulin (insulin resistance), people with type 2diabetes initially produces excess 
insulin. That excess allows converting the sugar in the diet to energy needed by tissues. 
Eventually the insulin producing cells in the pancreas deteriorate and lose their ability to secrete 
insulin this indicates that external insulin must be used to treat the disease(25). 
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1.5 Prevalence of Type 2 Diabetes 
T2D has become an epidemic in the 21st century. The total number of people worldwide with 
type 2 diabetes was expected to increase from 171 million in 2000 (2.8% of the world’s 
population) to 366 million (4.4% of the world's population) in 2030 (26). Unfortunately, the 
prevalence worldwide has already reached 366 million by 2011 according to the International 
Diabetes Federation (IDF), 80% of these individuals live in low- and middle-income countries 
(26).The majority of the expected increase in T2D cases will occur in people aged 45 to 64 years 
living in developing countries, and 183 million people (50%) with diabetes are undiagnosed.  
Clearly, the number of people with T2D diabetes is increasing in every country and the 
prevalence will continue to increase globally. It is projected that by 2030 the number would 
increase to 552 million .The number of people with diabetes is increasing due to population 
growth, aging, urbanization, and increasing obesity and physical inactivity (27).The increase in 
diabetes prevalence  will have a negative impact on costs, type2 diabetes caused at least 465 
billion dollars in healthcare expenditures in 2011; 11% of the total healthcare expenditures in 
adults (20-79 y) .The ‘top’ three countries in terms of the number of T2D cases are: China (90 
million in 2000;129.7  million in 2030)  India (61,3million in 2011;101 million in 2030), and the 
US (23.7 million in 2011; 29 million in 2030), and in Arab countries, the range between 4–21%, 
with the lowest being in Somalia and the highest in Kuwait (26).Six Arab countries are among the 
world’s leaders in terms of type II diabetes prevalence: these countries are Kuwait, Lebanon, 
Qatar, Saudi Arabia, Bahrain, and United Arab Emirates (UAE) (24,28),as shown in Table (1). 
In Palestine  in 2004, the reported prevalence in Palestinian Family Health Survey was 10.6% 
(8.7–12.5) versus an estimated 11.4% (9.7–13.4); in 2006, these values were 11.8% (9.8–13.8) 
and 12.3% (10.6–14.6), respectively  and  by 2010, the prevalence of type 2 diabetes had 
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increased to  14.5% (12.2–16.7), in this period, prevalence in men rose from 11.7% (9.7–13.6) to 
15.9% (13.4–18.1) and in women from 11.4% (9.3–13.3) to 13.2% (11.1–15.2). The forecasts for 
prevalence of diabetes are 20.8% (18.0–23.2) for 2020 and 23.4% (20.7–25.8) for 2030 (29). 
 
10 
 
 
Table 1.Ranking of the prevalence of type 2diabetes in Arabic and non-Arabic speaking countries   
International Diabetes Federation using IDF estimates for 2011, Arabic speaking countries   are shown in 
bold. IDF Diabetes Atlas (26). 
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1.6 Etiology of Type 2 Diabetes and Risk Factors 
 There are many different causes of this form of diabetes. Although the specific etiologies are 
unknown, type 2 diabetes can be caused by environmental (include behavioral factors) and 
genetic factors, insulin sensitivity and insulin secretion (30, 31).Although genes that predispose an 
individual to diabetes are considered to be an essential factor in the development of the disease, 
activation of a genetic predisposition is usually triggered by environmental  factors, particularly 
those who are overweight with low physical inactivity and gestational diabetes (32). 
The risk factors associated with type II diabetes can be grouped into two categories: modifiable 
and non-modifiable risk factors (33). 
a. Modifiable Risk Factors: 
Overweight and obesity (defined by a body mass index) has a strong relationship with type 2 
diabetes and it is the main risk factor for NIDDM because it plays essential role in causing 
insulin resistance (34). According to National Center for Health Statistics (NHANES) 78.5% of 
diabetics are overweight, and 45.7% are obese (35).  
Sedentary lifestyle: many epidemiologic studies show that increasing physical activity reduces 
risk of diabetes, whereas sedentary behaviors increase the risk such as prolonged television (TV) 
watching (36) extended time sitting, even with regular periods of exercise, they are still at greater 
risk for diabetes (37). 
 
Previously identified glucose intolerance (IGT and/or IFG):  impaired fasting glucose (IFG, 
fasting plasma glucose > 6.1 and < 7.0 mmol/L) here the blood glucose levels that are higher 
12 
 
than normal, but below the level of a person with diabetes also Impaired Glucose Tolerance(IGT; 
two-hour plasma glucose > 7.8 and < 11.1 mmol/L) (38).About 40-50% of people with IGT will 
develop type 2 diabetes (accompanied by increased risk of cardiovascular disease and 
microvascular complications) within ten years (39). 
b. Non-modifiable risk factors: 
Ethnicity: The risk of Type 2 diabetes is greater in African-American, Hispanic/Latin American, 
American Indian and Alaska Native, Asian-American, or Pacific Islander ethnicity. In some 
studies, the researchers found that the prevalence of diabetes was 16.1% among Native 
Hawaiians, 15.8% in Latinos, 15% in African-Americans, 10.2% in Japanese-Americans, and 
6.3% in whites. The reasons why people of these specific ethnicities are at greater risk of type 2 
diabetes are not fully understood and may be attributed to genetic effect (40). 
Family history of Type 2 diabetes: A family history of diabetes has a stronger risk factor for 
Type 2 diabetes than type 1.  Having one or more first-degree relatives with T2DM increases the 
odds of having the disease compared with someone without such relatives. The estimations vary, 
but the odds usually range from two to six times more likely (41).Since genetic tests are not 
currently available for type 2 of diabetes; the use of tools that include a family history of diabetes 
is potentially applicable way (42). 
 
Age: The chance of getting Type 2 diabetes increases with age. That's probably because people 
tend to exercise less, and gain weight as they age. There are combined effects of increasing 
insulin resistance and impaired pancreatic islet function with advanced age (43).However, there is 
age-related declines of pancreatic islet function and islet proliferative capacity (44). 
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History of gestational diabetes: GDM is defined as any degree of glucose intolerance with 
onset or first recognition during pregnancy (45).Screening for GDM is performed with a 50g oral 
glucose load given between 24 and 28 weeks gestation, followed by measuring the plasma 
glucose load after one hour.   If the level is >140 mg/dl, the patient is scheduled for a 3-hours, 
100g oral glucose tolerance test (OGTT). 
The following are the values considered to be abnormal during the 100 g of glucose OGTT: 
Fasting blood glucose level ≥95 mg/dl (5.33 mmol/L) 
1 hour blood glucose level ≥180 mg/dl (10 mmol/L) 
2 hour blood glucose level ≥155 mg/dl (8.6 mmol/L) 
 3 hour blood glucose level ≥140 mg/dl (7.8 mmol/L) (46) 
 It is a risk factor for Type 2 diabetes in the mother after pregnancy (47). About 30% of women 
will develop diabetes within 15 years. Therefore, regular screening for Type 2 diabetes is 
essential for women who have GDM (48), they have a 7.5-fold increased risk for the development 
of type 2 diabetes after delivery (49). 
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1.7 Complications of diabetes mellitus 
   Diabetes or hyperglycemia over many years leads to damage to several tissues in the body, 
producing so-called diabetic complications and they are separated into macrovascular 
complications (coronary artery disease, peripheral arterial disease, and stroke) and microvascular 
complications (diabetic nephropathy, neuropathy, retinopathy and dermopathy) as shown in 
Figure2(50). 
Microvascular Complications of Diabetes 
Diabetic retinopathy Blindness is one of the most common microvascular complications of 
diabetes resulting in blindness for over 10,000 people with diabetes per year.  Twenty years after 
the onset of diabetes over 60% of patients with type 2 diabetes will have some degree of 
retinopathy. Even at the time of diagnosis of type 2 diabetes, about a quarter of patients have 
established background retinopathy, and there is evidence that retinopathy begins to develop at 
least 7 years before the clinical diagnosis of type 2 diabetes. 
Diabetic retinopathy is due to microangiopathy affecting the retinal pre-capillary arterioles, 
capillaries, and venules. Damage is caused by both microvascular leakages from breakdown of 
the inner blood-retinal barrier and microvascular occlusion. (51, 52) 
Diabetic nephropathy: Diabetes has become the most common single cause of end-stage 
renal disease (ESRD) in the U.S. and Europe. The earliest clinical evidence of nephropathy is the 
appearance of low but abnormal levels of albumin in the urine (≥ 30 mg/day or 20 μg/min), 
referred to as microalbuminuria, thus diabetic nephropathy has been categorized into stages 
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based on the values of urinary albumin excretion (UAE): microalbuminuria and 
macroalbuminuria (53). 
A higher prevalence of   type 2 diabetes is found to have microalbuminuria and then they will 
have nephropathy after the diagnosis of their diabetes.  Because diabetes is actually present for 
many years before the diagnosis is made and because the presence of albuminuria may be less 
specific for the presence of diabetic nephropathy, 20–40% of type 2 diabetic patients with 
microalbuminuria progress to overt nephropathy, but by 20 years after onset of overt 
nephropathy, only ∼20% will have progressed to ESRD (54). 
Diabetic neuropathy: The diabetic neuropathies affect different parts of the nervous system 
and they may be focal or diffuse. Most common among the neuropathies are chronic 
sensorimotor distal symmetric polyneuropathy (DPN) and the autonomic neuropathies (DAN). 
Many mechanisms which are related to hyperglycemia such as polyol accumulation, injury from 
AGEs (advanced glycationend product), and oxidative stress may cause the injury to the 
peripheral nerves, so the -risk of developing diabetic neuropathy is proportional to both the 
magnitude and duration of hyperglycemia. 
More than 80% of amputations occur after foot ulceration or injury, which can result from 
diabetic neuropathy. The considerable morbidity and mortality that can result from diabetic 
neuropathy, it is important for clinicians to understand its manifestations, prevention, and 
treatment (55). 
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Classification of diabetic neuropathy 
Peripheral neuropathy  
Distal symmetric polyneuropathy (DPN) is defined of DPN for clinical practice as “the presence 
of symptoms and/or signs of peripheral nerve dysfunction in people with diabetes after the 
exclusion of other causes”   is present in at least 20% of adult diabetic patients.           
Cranial neuropathy   
Is extremely rare (0.05%), cranial nerves affected 111, 1V, V1,V11 , and are thought to occur 
due to a microvascular “infarct. 
Autonomic neuropathy   
This condition results in significant morbidity and may lead to mortality in some patients with 
diabetes. This neuropathy may lead to: postural hypotension, resting tachycardia, loss of 
sweating , gastrointestinal neuropathy such as gastroparesis, diabetic diarrhea  or constipation , 
urinary bladder atony and  erectile dysfunction:  The prevalence of erectile dysfunction in 
diabetic men ranges from 27 to 75% (56). 
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Macrovascular Complications of Diabetes: 
Type 2 diabetic patients are at a high risk for macrovascular complications, including diseases of 
coronary arteries, peripheral arteries, and carotid vessels. 
The central pathological mechanism in macrovascular disease is atherosclerosis, which leads to 
narrowing of arterial walls throughout the body .In diabetes; hyperglycemia, excess free fatty 
acid release, render arteries susceptible to atherosclerosis, impairs endothelial function, 
vasoconstriction increases inflammation, and promotes thrombosis.  In response to endothelial 
injury and inflammation, oxidized lipids from LDL particles accumulate in the endothelial wall 
of arteries. Angiotensin II may promote the oxidation of such particles then activation of the 
transcription factors nuclear factor κB (NF-κB) and activator protein 1 induces inflammatory 
gene expression, as a result increased production of inflammatory cytokines, and augmented 
expression of cellular adhesion molecules. Monocytes then infiltrate the arterial wall and 
differentiate into macrophages, which accumulate oxidized lipids to form foam cells. Once 
formed, foam cells stimulate macrophage proliferation and attraction of T-lymphocytes. 
T-lymphocytes, in turn, induce smooth muscle proliferation in the arterial walls and collagen 
accumulation. The net result of the process is the formation of a lipid-rich atherosclerotic lesion 
with a fibrous cap. Rupture of this lesion usually leads to acute vascular infarction, as shown in 
Figure 1 (50). 
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Figure 1. Endothelial Dysfunction in Diabetes. (The Journal of the American Medical 
Association JAMA. 2002 (57)). 
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Classifications of Atherosclerosis: 
Coronary artery disease (CAD) causes much of the serious morbidity and mortality in patients 
with diabetes, who have a 2- to 4-fold increase in the risk of CAD. The amplified incidence of 
CAD results from the aggregation of multiple risk factors, such as obesity, dyslipidemia, and 
hypertension, which occur in this population (58). 
Peripheral arterial disease (PAD) Individuals with diabetes have a 2- to 4-fold increase in the 
rates of PAD, more often have femoral bruits and absent pedal pulses, and have rates of 
abnormal ankle-brachial indices ranging from 11.9% to 16%. 
Cerebrovascular Disease and its effects in the coronary and lower extremity vasculature: 
Patients with diabetes have more extracranial atherosclerosis .Diabetes affects stroke outcome as 
well so it increases the risk of stroke-related dementia more than 3-fold, doubles the risk of 
recurrence, and increases total and stroke-related mortality (59). 
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Figure (2): Diabetes complications. (Diabetes care 2004,27)(60). 
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1.8 Genes and Type 2 Diabetes 
It has been known that T2D is a multifactorial disease with a strong genetic component 
interacting with environmental factors (61). Inheritance is a strong factor implicating inheritable 
genetics in type 2 diabetes:  in monozygotic twins (96%) supports a substantial contribution of 
genetic factors to T2D (62) also 40% having relatives (especially first degree) with type 2 
increases the risks substantially (63, 64). Many genes have been significantly associated with 
developing type 2 diabetes, until 2011 more than 36 genes have been found that contribute to the 
risk of type 2 diabetes, most of the discovered gene variants have been linked to beta-cell 
dysfunction, impaired glucose homeostasis and insulin secretion rather than insulin resistance 
(65). 
From these genes there are18 genes that affect β-cell function, namely :CAPN10(66) 
,CDC123/CAMK1D (67), CDKAL1 , CDKN2A/B(68) ,  ENPP1(69) ,FOXO1(70), HHEX(71), 
IGF2BP2, JAZF1 (72),KCNJ11(73) ,KCNQ1(74) ,MTNR1B(75), PPARGC1A(76) ,SGK1(77) , 
SLC30A8 (78), TCF7L2(79) , TSPAN8/LGR5 (80), and WFS1(81). The most promising 
candidate genes for human T2DM susceptibility arising from association studies are shown in 
Figure 3 on the next page: 
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Figure 3: Biological function of T2DM candidate genes arising from animal models and human 
association studies. Many genes have been associated with T2DM (Human Molecular Genetics, 
2006, Vol. 15) 
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1.9 TCF7L2, the most important type 2 diabetes gene: 
Prior to 2006, only two genes were implicated in type 2 diabetes (PPARG1 and KCNJ11) (84). 
After 2006, transcription factor-7–like 2 gene (TCF7L2) has been found as an unexpected 
suspect for type 2 diabetes by the DECODE group in Iceland (85). They reported that a common 
microsatellite in TCF7L2 gene region DG10S478 within intron 3 was associated with type 2 
diabetes in Icelandic case control sample. The overall estimated allelic relative risk was 1.56 
with P value of 7.8× 10−5 and the noncoding SNPs rs7903146 (C/T), and rs12255372 (G/T) 
were in strong linkage disequilibrium with DG10S478 (𝑟2=o.95 and 0.78 respectively) (86). They 
then  genotyped  three extra single nucleotide polymorphisms (SNPs) with the strong correlat ion 
to DG10S478 (rs7901695, rs11196205, and rs7895340) and showed association between all 
three SNPs and type 2 diabetes but the rs7903146 and rs12255372 were the strongest.(87,88)  
Subsequently, this association was confirmed in other populations such as Indians (89), French 
(90), Tunisians (91), Japanese (92), Mexican Americans (93), and West Africans (94)Amish (87), 
Polish (95) Chinese (96), Swedish(97) , Persian (98),and Palestine (99),all of these studies showed a 
strong association between TCF7L2 polymorphism and type 2 diabetes. 
Several genome wide association studies independently confirmed the presence of strong 
association of SNP rs7903146 of TCF7L2 with T2D. These data demonstrated that the genetic 
variants within TCF7L2 gene, especially T allele of SNP rs7903146, are associated with the risk 
of developing T2D in several ethnic groups (100).Specific variations in TCF7L2 gene increase 
risk of type 2 diabetes by 1.5 folds in heterozygotes and 2.4 folds in homozygotes, corresponding 
to a population attributable risk of 21%. This makes TCF7L2 variants the strongest known 
genetic risk factor for type 2 diabetes (101). 
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1.10 The mechanism by which TCF7L2 alleles predispose to diabetes 
TCF7L2 (also known as TCF-4)gene is a member of the T-cell factor (TCF)/lymphoid enhancing 
factor family of high mobility group box-containing transcription factors .It is a transcription 
factor  and key component of the Wingless-type integration site family (Wnt) signaling pathway, 
which exerts many important physiological and pathophysiological functions in different cell 
lineages and organs (101) .Signaling is initiated by the binding of Wnts to their receptor complex, 
which results in the release of beta -catenin from its degradation complex and translocation to the 
nucleus. In the nucleus, beta -catenin heterodimerizes with the TCF/lymphoid-enhancing factor 
family of transcription factors to regulate the expression of Wnt target genes like proglucagon 
and glucagon-like peptides 1 and 2 (102, 103) ,as shown in figure (4) . Potential mechanisms by 
which TCF7L2 variants influence type 2 diabetes include its role in adipogenesis, myogenesis,  
and pancreatic islet development, as well as transcription of the genes for proglucagon and the 
glucagon-like-peptides GLP-1 and GLP-2, which play a role in post-prandial insulin 
secretion(104). Additionally, TCF7L2 polymorphisms have been associated with impaired insulin 
secretion via direct effects on pancreatic islet beta cells (105,106), because it is required for β-cell 
survival and β-cell proliferation (107) so the polymorphism in this gene will increase the risk of 
diabetes by affecting insulin secretion, not insulin resistance (108), as shown in Figures(5,6). 
Thus, while the specific mechanism driving the development of type 2 diabetes remains unclear, 
there is sufficient evidence to demonstrate that TCF7L2 variants strongly predict the 
development of type 2 diabetes and/or the progression to diabetes from impaired glucose 
tolerance (106,109) 
. 
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Figure (4): The Wnt Signaling Pathway. Binding of Wnt ligand to a Frizzled/LRP-5/6 receptor complex 
leads to stabilization of hypophosphorylated β-catenin, which interacts with TCF/LEF proteins in the 
nucleus to activate transcription. In a canonical pathway, CKIα, GSK3β, APC, and Axin act as negative 
regulators and all other components act positively (Max Delbruck Center for Molecular Medicine (MDC) 
Berlin-Buch 2007) 
 
 
 
 
 
Figure (5): proposed pathophysiological pathway explaining how TCF7L2 risk genotypes predispose to 
type 2 diabetes. The risk genotype results in over expression of TCF7L2 in pancreatic β cells, which in 
turn results in reduced insulin secretion. Reduced insulin secretion results in a predisposition to type 2 
diabetes directly and also indirectly by increasing hepatic glucose output (110). 
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Figure (6): The TCF7L2 gene is located on the long (q) arm of chromosome 10 at position 25.3 
(ghr.nlm.nih.gov) (111). 
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Aims of the study: 
In this study we will focus on the Transcription Factor7Like2 gene (TCF7L2).It is a candidate 
gene which strongly related type 2 diabetes (T2D) locus identified to date (82). Common variants 
in this gene have a marked and reproducible effect on type 2 diabetes risk. This variation occurs 
at a single nucleotide polymorphism (SNP) within TCF7L2 (83). 
The aims of this study are the following: 
1. To determine the presence of association between T2DM and TCF7L2. 
2. To determine the rate of SNP rs7903146, and rs12255372 in patients with T2DM and 
compare that with normal non-diabetic controls. 
3. To determine the significance of the two SNPs individually and combined in T2DM 
patients as compared to controls.  
4. To determine the possibility of conducting genetic testing on TCF7L2 gene in predicting 
possible development of diabetes in healthy people.  
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Chapter 2 
Materials and Methods 
2.1 Sample Collection 
A total of 326 samples were collected from the West Bank and East Jerusalem. Blood was 
collected from all participants using vacutainer tubes with EDTA. Aseptic technique was 
followed to ensure patient safety and to minimize harm. All samples were stored at -80 o C until 
further DNA purification and subsequent molecular applications. The distribution of the samples 
is summarized in Table (2), Data collected for each sample included: age, gender, BMI, FBS, 
total cholesterol, blood pressure and family history of 1st degree relatives with T2D. This 
information is shown in Table (4) in the appendix. 
Table (2): Distribution of samples on the different regions of the West Bank and Jerusalem 
City Clinic Specimens 
Jerusalem UNRWA Clinic – Indian Hospice 60 
Bethlehem – South West Bank UNRWA Clinic- Khamashta 58 
 
Ramallah – Central West Bank 
Ministry of Health Clinics 46 
Diabetes Society – Al Bireh Center 18 
 
North West Bank  
 Nablus – Medicare Labs 15 
Tulkarem – Ministry of Health Clinics 11 
Qalqelia – Ministry of Health Clinics 41 
Controls  Clinics throughout West Bank and Jerusalem 77 
TOTAL 326 
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2.2. DNA Extraction: 
DNA was extracted from all samples by the salting out method (112,113). Briefly, white blood 
cells were lysed by lysing buffers; the supernatant was digested with Proteinase K at 56 o C for 
24 hours followed by salting out of the proteins by 5.3 M NaCl. The DNA fraction in the 
supernatant was purified by 100% ethanol for 24 hours at -20 o C and treated with 70% ethanol, 
dried and dissolved in Tris-HCL. The quality and quantity of the extracted DNA was checked by 
electrophoresis on 1% agarose as shown in Figure (7), and the DNA was stored at -20 o C for 
further work. 
2.3. Polymerase Chain Reaction (PCR): 
Amplification was conducted in a total volume of 25 µL. The2X ready PCR mix used for 
amplification (Thermo Scientific) consisted of: 1.25U Taq-Pol, 75 mMTris-HCL (pH 8.8), 1.5 
mM MgCl2, and 0.2mM of each dNTP. The reaction mixture contained: 12.5 ul master mix, 1.0 
uM each forward and reverse primers (Table 3), 1ug DNA template and 8.5 ul RNase free water 
to a total volume of 25 ul. The amplification was carried out in a C-1000 thermal cycler (Biorad, 
USA) according to the following program: an initial denaturation step at 95oC for 5 min, 
followed by 35 cycles of denaturation at 95oC for 30 s, annealing at 59 o C or at 64 o C 
(depending on the primer used) for 1 min, and a final extension step at 72o C for 5 min. 
Amplified PCR products were resolved by agarose gel electrophoresis (5V/60 min)using 1,5% 
agarose in Tris Acetate-EDTA (TAE) buffer containing 0.5 ug/ml of ethidium bromide. 
Molecular size ladder of 100 bp (Fermentans, Germany) was used to determine the size of the 
bands. The gel was viewed and photographed on a Gel-Doc System (BioRad, USA),as show in 
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Figures (8,9).The primers used for the amplifications were obtained from Invitrogen (Rhenium, 
Jerusalem) and summarized in Table (3). 
Primer 5’ – 3’ sequence Product 
size (bp) 
Annealing 
(oC) 
Ref. 
Forward 
Reverse 
For SNP 
rs12255372 
5’-CCCAGGAATATCCAGGCAAGGAT-3’ 
5’-CAAATGGAGGCTGAATCTGGCA-3’ 
120 59 114 
 
Forward 
Reverse 
For SNP 
rs7903146 
5’-TTAGAGAGCTAAGCACTTTTTAGGTA-3’ 
5’ACTAAGTTACTTGCCTTCCCTG-3’ 
120 64 114 
Table 3. PCR primers used for the amplification of single nucleotide polymorphisms of the 
TCF7L2 gene (114). 
 
 
2.4. Restriction Fragment Length Polymorphism – PCR (RFLP-PCR) 
Restriction of the 120 base pairs PCR products was performed using the restriction enzymes 
RsaI(Thermo)  for the SNP - rs7903146, and BseGI (Thermo) for the SNPrs12255372, following 
the manufacturer’s instructions. Specifically, 7.5 ul of the PCR product was suspended in 1X 
diluted buffer (BSA-provided with the enzyme) and incubated with 1.5U of the enzyme for 2 
hours at 37o for RsaI and  55oC for BseGI and 3% Agarose gel was used to separate the 
restriction fragments after digestion with the restriction enzyme. The C allele creates a restriction 
site and it gives two fragments less than 100 base pairs in non-mutated genes  ,the results were 
viewed on Gel-Doc System (BioRad, USA) and photographed, as shown in Figure (10,11),and 
the results are summarized on Table (4) in the appendix. 
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Figure 8: PCR product for rs7903146, 
Lanes 1 to 7 represents samples for PCR 
products for rs7903146, Lane 8, 100 bp 
ladder. 
1       2     3         4      5        6      7     8 
     1      2      3      4    5      6      7     8   
Figure 7:  
Lanes 1 to 8 representing different samples with 
DNA extraction by this procedure  
 
32 
 
 
 
Figure 9: PCR product for rs12255372. 
 
 
Figure 10: RFLP –PCR for rs7903146, the four control samples the band from right to left (non-
mutated) less than 100 base pair (bp) and the fifth band for single patient more than 100bp 
(mutated) 
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Figure 11: RFLP –PCR for rs12255372, Lanes 1 to 7 are 
Cases of mutated alleles with a band size of 120 bp. 
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2.5 Allele-specific polymerase chain reaction (ASPCR): The forward PCR primers were used 
for allele-specific PCR, for both mutations. The last nucleotide of the forward primer at 3’end 
was changed as shown in the ncbi sequence of the TCF7L2 gene below. The forward modified 
primer and the unchanged primer were tested with the reverse primer. This allowed us to confirm 
the presence of the mutations detected previously by the RFLP PCR.  
 FOR rs12255372 
tggcttgcaggtcagattttcatctttttaaattaattatcatagaaggagaaaacaactggatttcagaattgtcccttgaggtgtactggaaact
aaggcgtgagggactcataggggtctggcttggaaagtgtattgctatgtccagtttacacataaggatgtgcaaatccagcaggttagctga
gctgcccaggaatatccaggcaagaatgaccatattctgataattactcaggcctctgcctcatctccgctgcccccccgccccctgactctct
tctgagtgccagattcagcctccatttgaatgccaaatagacaggaaattagcatgcccagaatccacgtctttagtgcactctctccccagct
ccaaacctgttactgcttgtgttcaacatctcagtaaagctcaacaacatcgacccattacttaggcctcaaaccttgggtggcatcgtcgattg
ctctttt.(115). 
Primers: 
Forward Normal:ccaggaatatccaggcaagaatg 
ForwardMutated:ccaggaatatccaggcaagaatt 
 
For RS rs7903146 
 
TAATTGTAAATTGAATYGGACTAAAACCTTTCCAATTTTTTCAYATGTGAAGACATACACAAAA
GTTTTATTGGAGGGTTGCACATGTGAAAGAAAAAGGGAGAAAGCAGGATTGAGCAGGGGGAGCC
GTCAGATGGTAATGCAGATGTGATGAGATCTCTGCCRGACCAAAGAGAAGATTCCTTTTTAAAT
GGTGACAAATTCATGGGCTTTCTCTGCCTCAAAASCTAGCACAGCTGTTATTTACTGAACAATT
AGAGAGCTAAGCACTTTTTAGATACTATATAATTTAATTGCCGTATGAGGCACCCTTAGTTTTC
AGACGAGAAACCACAGTTACAGGGAAGGCAAGTAACTTAGTCAATGTCAGATAACTAGGAAAAG
GTTAGAGGRGCCCTGGACACAGGCCTGTRTGACTGAGAAGCTTGGGCACTTCACTGCTACATTT
CATYTCTTCGCTATAAACATTTTAGCTTTTTG(115). 
Forward Normal:AGAGAGCTAAGCACTTTTTAGATAC 
Forward Mutated:AGAGAGCTAAGCACTTTTTAGATAT 
 
Note: the same PCR reverse primers for both mutations were reused. 
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Figure 12: Allele specific PCR for rs7903146, Lanes 
1 to 7 are heterozygous samples with normal and mutated bands. 
 
 
Figure 13: Allele specific PCR rs7903146, above row from right to the left:(1)Normal CC, 
(2,3),homo-mutated sample TT, (4,5)normal sample CC ,(6,7)sample with mutated and normal 
bands hetero-mutated CT. 
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          Figure 14: Allele specific PCR rs12255372 
 
 
 
 
 
        Figure 15: Allele specific PCR rs12255372 
        Above row 1-7 all are heterozygous (GT) samples. 
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2.6 Statistical analysis: 
The data were analyzed using the SPSS v.21 program (Chicago, IL). The descriptive statistics 
were used to calculate frequencies: mean, standard deviation for all the variables. The 
independent-samples t-test was used to compare the differences between means. Some of the 
continuous variables were converted into categorical variables: age (30-50 years ,51-70years ,71-
85 years, diastolic blood pressure  (within 60-95mmHg  , greater than 96-110mmHg), systolic 
blood pressure ( within 90-139 mmHg , greater than140-210 mmHg ), Total cholesterol within 
(40-239 mg/dL, greater than 240-400 mg/dL),body mass index BMI (18-24.9(kg/m2),25- 29.9 
(kg/m2) ,30-55(kg/m2)),and fasting blood sugar FBS(less than 125 mg/dL, greater than 126 
mg/dL). Then the logistic regression was used to predict disease status (diabetes) and to adjust 
for different variables (covariates).  P -value less than 0.05 was considered significant. 
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Chapter 3 
Results 
In this case-control study a total of 326 participants were analyzed first by Restriction Fragment 
Length Polymorphism – PCR (RFLP-PCR) for TCF7L2 gene to detect the presence of SNPs for 
both sites rs7903146 and rs12255372. There were 47.4% (118/249) of the cases tested were 
positive for the mutation rs7903146 and 52.6 % (131/249) were negative. In the controls, there 
were 15.6% (12/77) positive and 84.4% (65/77) negative. For rs12255372: in cases37.8% 
(94/249) were positive, 62.2% (155/249) were negative and in controls 9.1% (7/77) were 
positive, 90.9% (70/77) were negative. 
 By using the t-test ,mean age for cases and controls was  significantly different  ,mean age for 
the cases was 58.66 ±9.59 years  and  the controls was 42.99 ±8.12 years. In this study, there was 
no significant difference between cases and controls regarding the gender of the participants. 
Mean BMI was 26.49 ± 3.54 kg/m2 for controls and 31.34±5.73 for cases. There was significant 
difference detected between the cases and controls at 0.05 level of significance (P <0.005) . 
Systolic blood pressure , Family history of type 2 diabetes, fasting blood sugar FBS and total 
cholesterol all of them showed significant difference between cases and controls at 0.05 level of 
significance (P <0.005) except for the  diastolic blood pressure was not statistically significant . 
All of these data are summarized in Table (5). 
By using RFLP-PCR,  after adjusting for all risk factors  and exclusion family history and FBS 
the logistic regression yielded significant odds ratio suggesting that the risk alleles confers 
significant risk for developing T2DM with reference to both SNPs: rs7903146 and rs12255372. 
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For rs7903146 odd ratio OR=3.0 (95%CI 1.24-7.24), rs12255372 OR= 5.5 (95%CI 1.97-15.19), 
before adjusting for all risk factors the results also were significant for rs7903146 OR= 4.88 
(95%CI 2.51-9.48) and rs12255372 OR=6.065 (95%CI 2.68-13.74). When the family history 
was included in the statistical analysis, the OR was 2.1(95%CI 0.81-5.2) for rs7903146 and 
3.3(1.12-9.1) for rs12255372. Although the OR was smaller when these two parameters were 
excluded from the analysis, there was a statistical significant result for both when compared with 
the controls. 
BMI for cases and controls was compared for both SNPs after adjusting for all risk factors and 
exclusion of family history and FBS.  There was significant difference at 0.05 level of 
significance (P <0.005) in the obese people only [OR= 3.5(1.3-9.5)].Statistical analysis for total 
cholesterol showed significant difference at 0.05 level of significance (P <0.005) between cases 
and controls [OR =13.9(1.6-122.67)] .Systolic blood pressure was significant OR =4.11(1.2-
14.2)  but diastolic was not significant OR=o.78(0.6-9.8), and the age was significant for  51-70 
years OR =12.7(5.55-29.03),for 71-85years OR = 28(3.3-233.3).Here the gender was not 
significant no difference between males and females to have the disease ,the results of this 
analysis in table (6). 
When studying the effect of each mutation alone after adjusting for other risk factors and 
exclusion of family history and FBS  , for rs7903146 it showed significant association with 
diabetes [OR=3.34(1.46-7.65)]. Comparing the following parameter for all participants (cases 
and controls),  BMI for the obese people, total cholesterol, systolic blood pressure ,and age all 
showed statistical significant results as shown in Table 7. Statistical significant results were also 
observed indicating positive association with T2DM when testing the previously mentioned 
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parameters for the second mutation rs12255372 [OR= 5.83(2.18-15.56)], results are shown in 
Table 8. 
We analyzed both mutations simultaneously (rs7903146 and rs12255372) in the total population 
tested for all the parameters with possible development of T2DM. Although we observed 
significant results the OR was 3.6(1.08-11.98), much smaller than when each mutation tested 
alone, OR was 15.52(5.42-44.5) as shown in Table 9. 
Allele specific PCR was used to detect the presence of SNPs on both alleles (homozygous 
genotype), or present in one allele only (heterozygous genotype), as shown in Table 10 and 11. 
Allele frequencies were calculated according to the following formula (116). 
Two alleles are possible, M (mutated) or N (normal) that can combine to give the following 
genotypes MM, MN, NN, so the allelic frequency for the M allele will be: 
f(M) = [(2 x M) + MN]/2×number of population 
The frequency for the N allele will be: 
f(N) = [(2 x N) + MN]/2× number of population, so 
f(M)+ f(N) =  1. (116) 
The allele specific frequencies were 0.1039 for rs7903146 T allele in the controls and three folds 
higher 0.297in the cases. For the second mutation rs12255372 T allele, the allele specific 
frequency was 0.065 in controls and about four folds 0.2168 in cases .OR was calculated for both 
SNPs to assess its association with type 2diabetes as shown in the same Tables 10 and 11 before 
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and after adjustment for sex, age, BMI, systolic, diastolic blood pressure and total cholesterol as 
covariates, the results showed evidence of association of the rs7903146 T allele with T2D in 
agreement with previous studies. The OR for heterozygous CT before adjustment was 5.77 (2.6-
12.6),P value 0.000, and after adjustment OR was 3.5(1.37-8.8), P value 0.009. The OR For 
homozygous before adjustment was 3.1(1.0-9.3), P value 0.043 and after adjustment was 3.7 
( 1-13.5  ) P value 0.044.  
For rs12255372 OR for heterozygous GT before adjustment was 5.12(2.3-11.8) P value 0.000, 
and after adjustment OR was 3.77(1.4-9.8) P value 0.007 giving significant results for both.  For 
rs12255372 homozygous TT, it was significant before adjustment OR was 4.5(1-19) P value 
0.047 but not significant after adjustment, OR was 3.6 (1-21) P value 0.15 thus it was not 
significant. 
As a result, for all diabetic participants who carry a single mutation or both mutations in this 
research, Bethlehem took first place ,Ramallah Jerusalem then the North (Qalqelya, Tulkarem, 
and Nablus),as shown in Table 12. 
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Table 5: General characteristics for the study population (mean ± SD), N (%) 
 total Controls (n=77) Cases (n=239) P 
Age  54.96 ± 11.4 42.99 ±8.12 58.66 ±9.59 0.000* 
Gender 
Males 
Females 
 
111 (34%) 
215 (66%) 
 
27(35.1) 
50(64.9) 
 
84(33.7) 
165(66.3) 
0.830 
BMI 30.2 ± 5.68 26.49 ±3.54 31.34±5.73 0.000 
FBS 152.05 ±70.16 86.79 ±9.85 172.22±68.48 0.000 
T. Cholesterol 181.19 ± 38.9 168 ±19.96 185.26±41.45 0.000 
Family history 
Yes 
No 
 
220 (67.5%) 
106 (32.5%) 
 
22(28.6) 
55(71.4) 
 
198(79.5) 
51(20.5) 
 
0.000 
BP (Sys) 127.34 ±17.77 118±11.25 130.22±18.44 0.000 
BP (Dias) 78.64 ±10.41 76.49±7.93 79.07±11.01 0.350 
Mutation 1 (rs7903146) 
 
Yes 
No 
 
 
126 (38.7%) 
200 (61.3%) 
 
 
12(15.6 %) 
65(84.4%) 
 
 
118(47.4%) 
131(52.6%) 
0.000 
Mutation 2 (rs12255372  ) 
 
Yes 
No 
 
 
101 (31%) 
225 (69%) 
 
 
7(9.1 %) 
70(90.9%) 
 
 
94(37.8%) 
155(62.2%) 
 
0.000 
Area 
1(Bethlehem) 
2(Ramallah) 
3(Jerusalem) 
4(controls=Different areas) 
5(North west bank) 
 
 
58 (17.8%) 
64 (19.6%) 
60(18.4%) 
77(23.4%) 
67(20.4%) 
 
0 
0 
0 
77(100%) 
0 
 
58(23.3%) 
64(25.7%) 
60(24.1) 
0 
76(26.6%) 
0.000 
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Table(6):*Adjusted for all risk factors in table, for rs7903146 and rs12255372# P < 0.05 include and 
without family history and Fasting blood sugar (FBS) 
 
 Number Crude OR 
 (95% CI) 
 
Adjusted OR 
(95%CI)* with 
FBS 
Adjusted OR  for all 
factors with family 
history except FBS 
Adjusted OR for 
all factors 
without family 
history and FBS 
Mutation rs7903146 
No (ref) 
Yes 
 
196 
130 
 
1 
4.88 (2.51-9.48)# 
 
1 
4.31 (1.02-18.18)# 
 
1 
2.1(0.81-5.2) 
 
1 
3.0(1.24-7.24) 
 
 
Mutationrs12255372 
No (ref) 
Yes 
 
 
225 
101 
 
 
1 
6.065(2.68-13.74) 
 
 
1 
0.41(0.08-2.1) 
 
 
1 
3.3(1.12-9.1) 
 
 
1 
5.5(1.97-15.19) 
BMI (kg/m2) 
18-24.9 
25-29.9 
30-55 
 
52 
111 
163 
 
1 
1.78 (0.910-3.48) 
9.86 (4.55-21.32)# 
 
1 
2.26 (0.41-12.5) 
7.83 (1.34-45.8) 
 
1 
1.12(.4-3.2) 
2.5(0.8-7.3) 
 
1 
1.24(0.49-3.2) 
3.5(1.3-9.5) 
Total 
cholesterol(mg/dL) 
40-239 
240-400 
 
 
275 
51 
 
 
1 
19.01(2.6-140.7) 
 
 
1 
27.2(1.7-434.7) 
 
 
1 
12(1.2-122) 
 
 
1 
13.9(1.6-122.67) 
Diastolic(mmHg) 
60-95 
96-110 
 
310 
16 
 
1 
4.87(0.63-37.49) 
 
1 
0.66(0.04-11.8) 
 
1 
0.8(.06-9.3) 
 
1 
0.78(0.6-9.8) 
Systolic(mmHg) 
90-139 
140-210 
 
242 
84 
 
1 
15.8 (6.40-39.01) 
 
1 
1.64 (0.4-7.2) 
 
 
1 
2.5(0.7-8.7) 
 
1 
4.11(1.2-14.2) 
Gender 
Male  
Female 
 
111 
215 
 
1 
1.06(0.6-1.8) 
 
1 
0.5(.15-1.7) 
 
 
1 
1.05(0.45-2.5) 
 
1 
0.92(0.416-2.04) 
Age(years) 
30-50 (1) 
51-70 (2) 
71-85(3) 
 
 
117 
180 
29 
 
1 
22.0(10.5-45.9) 
36.2(4.8-275.3) 
 
1 
16.97(5.2-56) 
44.4(3.8-521.6) 
 
1 
14.9( 6-36.6  ) 
29( 3.4-250.6 ) 
 
1 
12.7(5.55-29.03) 
28(3.3-233.3) 
Family history 
No 
Yes 
 
106 
220 
 
1 
9.7(5.4-17.4) 
 
1 
4.5(1.4-14.5) 
 
1 
6.1( 2.6-14.2 ) 
 
 
------------------------ 
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Table (7):*Adjusted for all risk factors in table, for rs7903146 # P < 0.05. 
 
 Number Crude OR (95% 
CI) 
 
Adjusted OR (95% 
CI)* with Family 
history 
Adjusted OR (95% 
CI)*without family 
history 
Mutation(1)rs7903146 
No (ref) 
Yes 
 
196 
130 
 
1 
4.88 (2.51-9.48)# 
 
1 
2.28(0.93-5.58) 
 
 
 
1 
3.34(1.46-7.65) 
 
 
BMI (kg/m2) 
18-24.9 
25-29.9 
30-55 
 
52 
111 
163 
 
1 
1.78 (0.910-3.48) 
9.86 (4.55-21.32)# 
 
1 
0.99(0.36-2.72) 
2.41(0.82-7.1) 
 
 
1 
1.032(0.42-2.51) 
3.81(1.45-10.03) 
 
Total  
Cholesterol(mg/dL) 
40-239 
240-400 
 
 
275 
51 
 
 
 
1 
19.01(2.6-140.7) 
 
 
1 
11.24(1.15-109.6) 
 
 
1 
12.12(1.42-103.2) 
Diastolic(mmHg) 
Normal 
Abnormal 
 
310 
16 
 
1 
4.87(0.63-37.49) 
 
1 
0.83(0.07-9.66) 
 
1 
0.85(0.73-9.82) 
Systolic (mmHg) 
Normal 
Abnormal 
 
242 
84 
 
1 
15.8 (6.40-39.01) 
 
1 
2.23(0.66-7.51) 
 
 
1 
3.57(1.095-11.62) 
 
Gender 
Male  
Female 
 
111 
215 
 
1 
1.06(0.6-1.8) 
 
1 
1.12(0.49-2.55) 
 
1 
1.01(0.47-2.15) 
Age 
30-50 (1) 
51-70 (2) 
71-85 (3) 
 
 
 
117 
180 
29 
 
1 
22.0(10.5-45.9) 
36.2(4.8-275.3) 
 
1 
15.25(6.21-37.4) 
28.26(3.27-244.23) 
 
1 
12.35(5.544-27.53) 
23.97(2.93-196.34) 
Family history 
No 
Yes 
 
106 
220 
 
1 
9.7(5.4-17.4) 
 
1 
7.41(3.26-16.82) 
-------------------- 
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Table (8):*Adjusted for all risk factors in table, for rs12255372# P < 0.05. 
 Number Crude OR 
(95% CI) 
 
Adjusted OR 
(95% CI) 
*with Family 
history 
Adjusted OR (95% CI)* 
without Family history 
Mutation(2)rs12255372 
No (ref) 
Yes 
 
225 
101 
 
1 
6.065(2.68-
13.74) 
 
1 
3.5(1.28-9.5) 
 
 
1 
5.83(2.18-15.56) 
BMI (kg/m2) 
18-24.9 
25-29.9 
30-55 
 
 
52 
111 
163 
 
1 
1.78 (0.910-
3.48) 
9.86 (4.55-
21.32)# 
 
1 
1.1(0.38-
2.99) 
2.3(0.8-6.74) 
 
1 
1.19(0.48-2.97) 
3.26(1.22-8.74) 
 
Total  
Cholesterol(mg/dL) 
40-239 
240-400 
 
 
275 
51 
 
 
 
1 
19.01(2.6-
140.7) 
 
 
1 
12.77(1.33-
123.1) 
 
 
1 
15.57(1.83-32.8) 
Diastolic(mmHg) 
Normal 
Abnormal 
 
310 
16 
 
1 
4.87(0.63-
37.49) 
 
1 
0.66(0.06-
7.9) 
 
1 
0.65(0.05-8.1) 
Systolic(mmHg) 
Normal 
Abnormal 
 
242 
84 
 
1 
15.8 (6.40-
39.01) 
 
1 
2.53(0.73-
8.8) 
 
1 
4.4(1.29-14.99) 
 
Gender 
Male  
Female 
 
111 
215 
 
 
1 
1.06(0.6-1.8) 
 
1 
1.12( 0.49-
2.58) 
 
1 
1.07(0.5-2.3) 
Age  
30-50 (1) 
51-70 (2) 
71-85 (3) 
 
 
 
117 
180 
29 
 
1 
22.0(10.5-
45.9) 
36.2(4.8-
275.3) 
 
1 
15.77( 6.46-
38.54 ) 
31.71(3.74-
268.52) 
 
1 
13.8(6.13-30.96) 
33.99(4.15-278.4) 
Family history 
No 
Yes 
 
106 
220 
 
1 
9.7(5.4-17.4) 
 
1 
6.90(3.02-
15.81) 
----------------------------------------- 
 
 
 
46 
 
Table (9):*Adjusted for all risk factors in table. For interaction and combination between 
mutations rs7903146 and rs12255372 together, # P < 0.05. 
** (0): have not both mutations, (1): have single mutation either rs7903146or rs12255372, (2): 
have both mutations rs7903146 and rs12255372. 
 
 Adjusted OR 
(95% CI) * with 
Family history 
Adjusted OR (95% CI) * without Family 
history 
Mutation(1)rs7903146+mutation(2)rs12255372 
No (ref)(0)** 
Yes(1) 
      (2) 
 
 
1 
10.143.34-30.8) 
2.21(0.65-7.5) 
 
 
 
 
1 
15.52(5.42-44.5) 
3.6(1.08-11.98) 
 
 
BMI (kg/m2) 
18-24.9 
25-29.9 
30-55 
 
1 
1.27(0.43-3.77) 
3.4(1.08-10.9) 
 
 
 
1 
1.29(0.48-3.46) 
4.4(1.53-12.8) 
 
Total 
 Cholesterol (mg/dL) 
40-239 
240-400 
 
 
1 
13.3(1.21-
147.7) 
 
 
1 
15.1(1.064-139.0) 
Diastolic(mmHg) 
Normal 
Abnormal 
 
1 
0.56(0.042-7.5) 
 
1 
0.57(0.042-7.85) 
Systolic 
Normal 
Abnormal 
 
1 
2.88(0.78-
10.66) 
 
 
1 
4.93(1.37-17.8) 
 
Gender 
Male  
Female 
 
1 
0.76(0.3-1.89) 
 
1 
0.65(0.27-1.54) 
Age 
30-50 (1) 
51-70 (2) 
71-85 (3) 
 
 
 
1 
19.3(7.5-49.9) 
34.7(3.82-
315.02) 
 
1 
17.14(7.1-41.45) 
33.53(3.85-291.8) 
Family history 
No 
Yes 
 
1 
5.46(2.3-13.01) 
---------------------------------------------------- 
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Table (10): The genotype frequency of the r7903146 polymorphism in the TCF7L2 gene 
Genotype Controls T2DM P value 
(For crude OR) 
Crude OR 
(95%CI) 
Adjusted OR 
(95% CI) 
P 
value CC 65 131 reference    
CT 8 88 0.000 5.77 (2.6-12.6) 3.5(1.37-8.8) 0.009 
TT 4 30 0.043 3.1(1.0-9.3) 3.7( 1-13.5 ) 0.044 
Total 77 249     
Allele frequency 
Allele C 
Allele T 
 
0.896 
0.1039 
 
0.7028 
0.297 
    
 
Distribution of genotype and allele frequencies for polymorphism within the TCF7L2 gene 
rs7903146 , and  the analysis before and after  incorporates sex, age, BMI ,systolic and diastolic 
blood pressure  and total cholesterol  as covariates, minimizing potential confounding ( OR, odds 
ratio, CI, confidence interval ). 
Table 11: The genotype frequency of the rs12255372 polymorphism in the TCF7L2 gene 
Genotype 
 
Control T2DM 
 
P value 
 
Crude OR   Adjusted OR  P value 
GG 69 154 reference    
GT 6 76 0.000 5.12(2.3-11.8) 4.0(1.4-10) 0.009 
TT 2 19 0.047 4.5(  1-19 ) 3.6(1-21) 0.15 
Total 77 249     
Allele frequency 
Allele G 
Allele T 
 
0.935 
0.065 
 
0.783 
0.2168 
    
 
Distribution of genotype and allele frequencies for polymorphism within the TCF7L2 gene 
rs12255372 and the analysis before and after  incorporates sex, age, BMI ,systolic and diastolic 
blood pressure  and total cholesterol  as covariates, minimizing potential confounding ( OR, odds 
ratio, CI, confidence interval ) 
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Table (12): Distribution of TCF7L2 gene positive results for mutations rs7903146 and 
rs12255372 of Diabetes Mellitus in West Bank and Jerusalem, Palestine:  
 
 
 
 
 
 
 
 
Area 
 
rs7903146 Ratio rs12255372 Ratio Both 
mutations 
Ratio 
Bethlehem 31 31/58=53.4% 30 30/58=51.7% 15 15/58=25.8% 
Ramallah 34 34/64=53% 24 24/64=37.5% 13 13/64=20% 
Jerusalem 31 31/60=51.6% 18 18/60=30% 10 10/60=16.6% 
North West 
Bank 
22 22/67=32.8% 19 19/67=28.3% 7 7/67=10.4% 
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Chapter 4 
Discussion 
The aim of this case control study was to evaluate the association between TCF7L2 gene in 
T2DM. Two SNP’s rs7903146C/T, rs12255372G/T in the TCF7L2 gene were investigated in 
diabetic patients and compared to a control group. RFLP PCR was performed using two 
restriction enzymes RsaI and BseGI to identify the presence of these two specific mutations in 
the study population. Furthermore, allele specific PCR was performed to substitute for DNA 
sequencing on one hand and to genotype the TCF7L2 gene as homo or heterozygous. We used 
SPSS v.21 to compare the results obtained between the case and control groups.  
The results of the RFLP showed the presence of significant association at 0.05 level of 
significance between the two investigated single nucleotide polymorphisms and T2DM. The 
details of the results are shown in Tables 10 and 11.  This is the first study that evaluated the 
association of two mutations with T2DMin this country. A study conducted by Abdeen et al. in 
2010 in Al-Quds University (99) on rs7903146C/T reported similar results as compared to ours. 
We used allele specific PCR to genotype the gene investigated instead of the sequencing analysis 
they used. Previous studies evaluated the association of both mutations as used by us conducted  
by researchers in the US, Poland, Amish population in the US ,Finnish, and French have similar 
results for  rs7903146 C/T, rs12255372 G/T both of these SNPs are associated with T2DM 
(90,95,96,117,118,120). 
The study performed on the association of TCF7L2 gene and T2DM on the Palestinian 
population by Abdeen et al., reported an association between thers7903146 T allele and T2DM 
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as reported in this study. The population selected for Abdeen study was restricted to one 
geographic area, Ramallah, Palestine. Their samples were collected from the UNRWA clinics in 
the Ramallah area. Our study is more comprehensive and more representative of the Palestinian 
population and the different geographical regions of Palestine.  Furthermore, our study addressed 
the two strongest and most commonly involved alleles in T2DM, while Abdeens study addressed 
only one allele.  
A study conducted on Israeli Ashkenazi Jewish population on 2010 (121).This study found a 
strong independent association between HNF4 and WFS1 alleles with T2DM in this ethnic 
group. They also evaluated rs7903172 T allele and reported a weak association with T2DM 
contrary to results obtained in our study.   The allele frequency for this allele was high than that 
reported by the Israeli study indicating that this allele is strongly associated with T2DM in 
Palestinian population as compared to weak association among the Ashkenazi Jews.  
In a Mexican study conducted by Parra EJ, in 2007(114) reported significant association between 
rs12255372 while  SNP rs7903146 showed similar trends, but its association with T2D is not as 
strong as rs12255372. This may reflect geographic distribution regarding the polymorphism of 
TCF7L2 gene.  
Although most of the literature published to evaluate the polymorphism of the TCF7L2 genes 
relied on sequencing analysis, we adopted the allele specific PCR method (122,123,124,125). Allele 
specific PCR is a reliable technique that has high specificity and sensitivity (126,127,128,129,130). 
In addition, it is cost effective, rapid and not labor intensive. The results obtained by this method 
in this study were similar to results obtained by others who used the DNA sequencing (99,114, 90, 
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95, 96, 117, 118, 120). The results obtained by this method accurately identified the genotypes and 
nature of polymorphism of the TCF7L2 gene among the Palestinian population tested.  
The nature of TCF7L2 gene polymorphism differs from one geographic area and another. In 
China for example, they did not detect association of the risk allele (rs7904146 T and 
rs12255372 T) with type 2 diabetes as detected in our study. These risk alleles were found to be 
rare with low frequencies in the Chinese population (131). A possible explanation for this result 
could be attributed to differences in the ethnic background among the Chinese population or the 
effects of environmental factors, such as life-style as well as geographical distribution of these 
alleles. 
By using  RFLP –PCR with exclusion family history and FBS because both are very significant 
and strongly related to type 2 diabetes so if both included in analysis the association between two 
mutations and the disease will be less significant thus both were excluded. The same for 
rs7903146 after adjusting for other risk factors ,age, sex , BMI, total cholesterol, and blood 
pressure  it showed significant association with diabetes OR=3.34(1.46-7.65, as shown in table 
(7). 
The allele specific PCR for rs12255372 T allele has a higher frequency in the patients with T2D 
than the controls as shown in Table 11. It was noteworthy that the heterzygote genotype for this 
allele was statistically significant before and after adjustment for the confounding factors (risk 
factors, age, sex, BMI, total cholesterol, and blood pressure). Contrary to that, it was found that 
for the homozygous genotype of this allele was statistically significant before adjustment but not 
statistically significant after adjustment for the confounding factors. This can be due to scarcity 
52 
 
of this mutation among the control group. Similar results have been reported by a Mexican study 
but on the rs12255346 T allele (114). 
The interaction between mutations rs7903146 and rs12255372 on the TCF7L2 gene and T2DM 
combined had an OR= 3.6(1.08-11.98) but the OR was 15.52(5.42-44.5) when these mutations 
were considered singly as shown in Table9. The differences in the OR in these situations may be 
explained by the considering that every mutation works independently with distinct mechanism 
and it is not common to find both mutations together in the same individual. The exact 
mechanisms, by which genetic variation within the intron of the TCF7L2 gene that confer 
susceptibility to Type 2 diabetes remain to be elucidated. Genetic variations near the 3′ end of 
the TCF7L2 gene may affect the action of TCF7L2, through the regulation of alternative splicing 
(120). 
There was difference in the mutation distribution between south to north Palestine, mainly 
Bethlehem (south) occupied the first place in diabetic patients who carry the mutations in 
TCF7L2 gene,  many reasons may interact like high trend of positive family history for diabetes 
among the study population  in the south may be due to relative marriage contributing to the 
perpetuation of genetic disorders or adopting of adverse health behaviors like eating habits, 
smoking and other environmental factors that differ from one geographic region to another in 
Palestine, which contribute to development of diabetes disease when interacting with a 
susceptible gene. 
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A limitation of this study could be that the number of the control participants was relatively 
small and may have caused some bias when comparing age and gender, blood pressure and 
cholesterol, these confounding factors have been adjusted in the statistical analysis to obtain a 
more real picture of the association between T2DM and TCF7L2 gene. 
As a conclusion, a significant association of the TCF7L2 variant with type 2 diabetes risk was 
observed in Palestinians for both polymorphisms rs7903146 and rs12255372, but rs7903146 was 
more significant than rs12255372 between Palestinians. As known, the strongest association with 
T2DM risk in most reported studies is with rs7903146 that shows a stronger association with 
type 2 diabetes than rs12255372. 
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Chapter 5 
Incretin-Based Therapy in the Prediabetic Stage 
Pre-diabetes  individuals  who are  at high risk for developing Type 2 diabetes , many causes are 
associated for developing T2DM  such as family history,  overweight or obese, women who have 
had gestational diabetes with high birth weight babies , people with IGT or IFG, they have lost 80% 
of their β-cell function, they have an approximate 10% incidence of diabetic retinopathy and 
genetics factors that multiple genetic defects at different loci will be found that confer varying 
degrees of predisposition to Type 2 diabetes .The clinical implications of these findings for the 
treatment of Type 2 diabetes are that the physician must intervene early (132,133,134). 
Variety of pharmacologic treatment options management of patients with pre-diabetes could be used 
after using some of the strategies that includes medical nutrition therapy to achieve weight loss in 
individuals who are overweight or obese, appropriately prescribed physical activity, avoidance of 
tobacco products, and stress reduction (135,136). The goals of early (pre-diabetic) glucose-directed 
therapies are to normalize glucose levels, prevent or delay progression to diabetes, prevent 
microvascular complications, and modify other risk factors such as obesity, hypertension, and 
dyslipidemia (134). 
There are many hypoglycemic drugs that can be used such as the oral diabetes drugs like metformin 
(glucophage) which has a biguanide that improves the ability of insulin to suppress excess hepatic 
glucose production in both the fasting and postprandial states (137). Acarbose (class – alpha-
glucosidase inhibitors) an alpha-glucosidase inhibitor, works by delaying carbohydrate absorption 
from the intestine also used for high risk of diabetes (138). Pioglitazone or rosiglitazone (class – 
thiazolidinediones [TZDs]) are effective in preventing T2DM in 62% to 72% of high-risk patients, 
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TZDs increase peripheral insulin sensitivity, with the benefit of increased HDL cholesterol and 
decreased LDL cholesterol (139). Exenatide (class – glucagon-like peptide-1 [GLP-1] inhibitor or 
Byetta) as a novel treatment option for type 2 diabetes mellitus it belongs to the group of incretin 
mimetics: augments pancreas response, increases insulin secretion in response to eating meals, 
suppresses pancreatic release of glucagon in response to eating, has a subtle yet prolonged effect to 
reduce appetite, promote satiety via hypothalamic receptor (140) . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
56 
 
5.1 Genetic Variants in TCF7L2 Gene and Incretin Effect 
The TCF7L2 polymorphisms are thought to make a greater contribution to the development of 
Type 2 diabetes than other genetic markers (141). The TCF7L2 variants mainly in the Two 
intronicTCF7L2 polymorphisms, rs7903146 C>T and rs12255372 G>T, have been the strongest 
and most consistent predictors of increased Type 2 diabetes risk because they are associated with 
a reduced incretin effect (142,143,144). 
Incretins are gut hormones that potentiate insulin secretion after meal ingestion in a glucose-
dependent manner. The two best-studied incretins, glucose-dependent insulinotropic polypeptide 
(GIP) secreted from the L-cells of the distal ileum and glucagon-like peptide-1 (GLP-1) secreted 
from the K-cells in the duodenum and jejunum. After secretion, incretins are rapidly degraded 
due to the action of dipeptidyl peptidase-4 (DPP-4), a ubiquitous enzyme found on the surface of 
epithelial and endothelial cells but also found in plasma (145). 
There are many biological actions of incretins related to pancreas mainly for GLP-1 that 
increases insulin and inhibits glucagon secretion in a glucose-dependent manner, GLP-1 also 
increases insulin synthesis, confers glucose sensitivity to glucose-resistant beta cells, stimulates 
beta-cell proliferation and neogenesis, and inhibits beta cell apoptosis, also there are another 
physiological actions for GLP-1 in other organs in the body, as shown in Figures 16 (146). 
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Figure 16: Physiological Roles of Endogenous GLP-1.Campbell and Drucker, Pharmacology, 
Physiology, and Mechanisms of Incretin Hormone Action, Cell Metabolism (2013), 
http://dx.doi.org/10.1016/j.cmet.2013.04.008 
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Now a day incretin-based therapies offer a new approach for the management of type 2 diabetes, 
with a mechanism of action distinct from any existing class of glucose-lowering agents. These 
drugs improve the body's ability to control blood glucose by increasing active concentrations of 
glucagon-like peptide-1 (GLP-1).Two approaches have been used to enhance the action of 
GLP1. First, incretin mimetics (exenatide) or analogues (liraglutide) act as agonists at the GLP-1 
receptor to mimic the effect of endogenous GLP-1, and dipeptidyl peptidase IV (DPP-4) 
inhibitors, which prevent metabolism of the native peptide and extend its activity (147). 
According to our research study, using the incretins for non-diabetic subjects with SNPs in the 
TCF7L2 gene (TT or TC at rs7903146) or (TT or TG at rs12255372) might even be disease-
modifying agents that have the potential to delay the onset or slow the progression of diabetes 
(148). 
As known, TCF7L2 encodes a transcription factor involved in Wnt signaling, important for the 
development of the pancreatic β-cells and for β-cell survival. Therefore, TCF7L2 variants may 
underlie the loss of incretin effect (148),Human non-diabetic subjects with SNPs in the TCF7L2 
gene (TT or TC at rs7903146) or   (TT or TG at rs12255372) exhibit reduced insulin secretion in 
response to oral but not intravenous glucose, with no differences in circulating GLP-1 or GIP 
levels or insulin sensitivity, consistent with the notion that reduction in TCF7L2 impairs beta cell 
incretin responsivity (149).Non-diabetic carriers of the diabetes-associated TCF7L2 variant allele 
exhibit normal beta cell function in response to exogenous GLP-1 infusion during hyperglycemic 
clamp (150). In contrast, insulin secretion in response to oral glucose or a mixed meal was 
reduced in non-diabetic carriers of rs7903146 or rs12255372, and the insulinotropic response to 
exogenous GLP-1 and GIP was impaired during a hyperglycaemic clamp (151).  
 
59 
 
Therefore, incretin-based therapy is a valuable add-on to the therapeutic spectrum for pre- 
diabetes that offers the possibility of targeting many pathophysiological abnormalities associated 
with the disease, but this needs to be proven by clinical trials. 
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Appendix 5. 
Number Area Age Gender BMI BP FBS T-Choles. Family 
History 
rs12255372 rs7903146 
1 B 52 F 23 100/70 211 212 Y P P 
2 B 56 F 25 110/60 258 191 Y P P 
3 B 63 F 23 120/80 196 200 Y P P 
4 B 50 F 32 130/80 152 200 Y P N 
5 B 46 M 30 120/80 140 187 Y P P 
6 B 61 F 34 120/80 170 234 N P N 
7 B 68 F 24 100/70 129 196 Y N P 
8 B 47 F 40 130/80 140 210 Y P N 
9 B 67 F 26 138/88 104 247 N P P 
10 B 44 F 34 120/80 233 196 Y P P 
11 B 80 M 24 130/80 94 206 Y N N 
12 B 81 M 28 138/80 158 190 Y P P 
13 B 69 F 33 130/60 139 150 Y P N 
14 B 59 M 29 150/90 223 190 Y N N 
15 B 59 F 37 110/50 83 137 Y P P 
16 B 51 F 29 150/90 170 182 Y N N 
17 B 80 M 36 130/60 162 103 Y P P 
18 B 46 M 34 150/100 112 206 Y N N 
19 B 60 F 28 130/180 151 210 Y N P 
20 B 62 F 30 110/80 124 130 Y N N 
21 B 67 F 29 110/80 222 168 Y P N 
22 B 64 F 28 130/70 129 192 N N N 
23 B 57 F 34 120/80 146 174 Y P P 
24 B 74 F 36 120/80 180 198 Y P P 
25 B 57 F 32 110/72 105 166 Y P P 
26 B 50 F 24 90/60 305 202 Y N P 
27 B 67 F 40 150/70 191 204 Y N P 
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Number Area Age Gender BMI BP FBS T-
Choles. 
Family 
History 
rs12255372 rs7903146 
28 B 78 F 31 130/60 118 152 Y N P 
29 B 61 M 29 138/88 126 181 Y P N 
30 B 51 F 44 130/82 304 143 Y N N 
31 B 58 F 32 130/70 136 202 Y P N 
32 B 63 F 45 130/80 134 192 Y P N 
33 B 56 F 44 110/70 188 162 Y P N 
34 B 53 F 25 150/90 215 194 Y P P 
35 B 67 M 41 150/60 347 269 Y N P 
36 B 71 F 30 120/80 136 65 N N N 
37 B 66 F 42 130/80 254 238 Y N N 
38 B 48 M 29 120/60 120 196 Y N N 
39 B 46 F 29 110/80 170 148 Y P N 
40 B 43 F 34 120/80 183 211 N P P 
41 B 43 F 29 110/70 140 170 Y N N 
42 B 68 M 28 138/70 203 153 N P N 
43 B 72 F 35 180/90 267 220 N P P 
44 B 56 M 26 120/70 97 183 Y N N 
45 B 53 M 26 130/84 118 150 Y P P 
46 B 64 F 36 150/80 296 190 Y N N 
47 B 50 F 34 120/70 108 178 Y P P 
48 B 52 F 33 100/60 159 287 Y P P 
49 B 67 F 38 120/70 170 255 Y P N 
50 B 59 F 38 130/80 253 278 Y N P 
51 B 63 F 27 130/80 164 212 Y N P 
52 B 69 F 28 138/80 239 230 Y N P 
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Number Area Age Gender BMI BP FBS T-
Choles. 
Family 
History 
rs12255372 rs7903146 
53 B 74 M 28 130/80 127 217 Y N P 
54 B 75 M 34 134/70 134 188 Y P P 
55 B 68 F 32 150/110 120 153 Y N P 
56 B 63 F 37 130/80 191 295 Y P P 
57 B 58 F 43 128/88 169 208 Y P N 
58 B 55 F 39 120/86 233 135 Y P P 
59 R 55 F 24.9 135/88 237 180 T N P 
60 R 70 M 34.4 134/91 230 231 Y N P 
61 R 60 F 34 169/87 257 158 Y P N 
62 R 56 M 27.4 150/85 236 244 Y N P 
63 R 73 F 33.5 152/79 240 221 N P P 
64 R 64 F 28.4 120/80 234 248 N P P 
65 R 56 F 30.8 127/65 131 183 Y P P 
66 R 64 F 33 144/75 85 178 Y N P 
67 R 73 M 27.6 122/66 87 128 Y N P 
68 R 48 F 34 122/66 281 230 Y P P 
69 R 62 F 30 133/77 233 114 Y N P 
70 R 66 F 33 148/79 100 216 Y N P 
71 R 66 F 31.6 143/82 101 145 Y N P 
72 R 73 F 27 149/87 128 219 Y P N 
73 R 42 M 24.9 146/89 136 142 Y N N 
74 R 54 M 33.6 123/87 148 216 Y P N 
75 R 46 M 31.3 116/67 94 240 Y P N 
76 R 64 M 28 122/70 139 133 Y P P 
77 R 54 M 29.6 144/90 68 127 Y N P 
78 R 39 F 36 130/85 140 194 Y P N 
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Number Area Age Gender BMI BP FBS T-
Choles. 
Family 
History 
rs12255372 rs7903146 
79 R 63 F 44 126/72 164 201 Y N N 
80 R 51 F 32 134/90 250 161 Y P P 
81 R 47 M 36 112/73 309 149 Y N N 
82 R 62 M 26 129/70 145 173 Y N P 
83 R 75 F 33 90/60 118 167 Y N P 
84 R 55 F 25 120/80 143 240 Y P P 
85 R 61 M 40 100/50 165 111 Y N N 
86 R 63 F 46 100/70 123 318 Y N N 
87 R 43 M 33 110/70 156 216 Y P N 
88 R 36 F 24 130/88 220 180 Y P N 
89 R 72 M 26 130/80 135 234 N N P 
90 R 66 M 28 134/83 197 190 Y N N 
91 R 54 M 29 113/65 159 186 N P P 
92 R 57 M 29 146/79 168 171 Y P N 
93 R 48 F 23 109/68 148 151 Y N P 
94 R 45 F 29 90/50 173 166 Y P N 
95 R 67 F 47 160/70 261 226 Y N P 
96 R 53 F 33 90/60 156 249 Y N N 
97 R 53 F 37 110/55 403 225 Y P P 
98 R 58 F 35 100/70 255 128 Y N P 
99 R 79 M 23 120/80 150 113 Y N N 
100 R 65 F 30 110/70 165 131 Y N N 
101 R 57 F 33 100/60 159 265 Y N N 
102 R 50 F 27 90/60 121 212 N N P 
103 R 60 F 33 100/60 257 176 Y N P 
104 R 44 M 23 100/60 162 174 Y P N 
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Number Area Age Gender BMI BP FBS T-
Choles. 
Family 
History 
rs12255372 rs7903146 
105 R 69 F 33 120/60 116 207 Y N P 
106 R 54 M 28 140/80 142 120 Y P N 
107 R 51 M 30 204/110 155 218 Y N P 
108 R 76 M 20 85/50 434 214 Y N N 
109 R 59 M 36 130/80 170 243 Y P P 
110 R 74 M 31 95/50 114 162 Y N P 
111 R 68 M 30 135 200 190 Y N P 
112 R 45 M 28 90/60 109 172 Y N N 
113 R 61 M 29 160/90 220 170 Y N P 
114 R 38 M 32 120/89 153 191 Y N P 
115 R 62 M 31 160/90 128 206 N N N 
116 R 73 M 39 100/70 136 182 Y N N 
117 R 60 F 39 130/69 206 180 Y P N 
118 R 50 F 25 100/70 90 186 Y N N 
119 R 75 F 32 140/90 129 268 Y P P 
120 R 43 M 37 167/92 238 228 Y N P 
121 R 52 F 31 130/85 280 238 Y N N 
122 R 60 M 30 140/90 117 243 Y N P 
1537 J 55 F 33 140/90 155 188 N P P 
1538 J 64 F 39 126/72 157 169 N P P 
1539 J 50 F 34 150/84 248 139 Y N P 
1540 J 69 M 29 130/84 128 202 Y N P 
1541 J 65 M 26 130/85 256 222 Y N P 
1542 J 71 F 27 158/72 219 160 Y P P 
1543 J 51 F 36 140/90 126 202 Y P P 
1544 J 64 F 30 130/82 80 189 Y N N 
1545 J 57 F 27 150/86 159 119 Y N N 
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Number Area Age Gender BMI BP FBS T-
Choles. 
Family 
History 
rs12255372 rs7903146 
1546 J 57 F 36 120/86 169 182 Y P P 
1547 J 53 F 31 120/82 179 248 Y N N 
1548 J 45 F 34 140/100 127 192 Y P N 
1549 J 57 F 32 150/96 120 159 Y N P 
1550 J 48 F 30 110/82 174 216 Y N P 
1551 J 55 M 31 130/82 110 205 N P P 
1552 J 68 F 31 130/100 129 158 Y P N 
1553 J 63 F 33 160/80 114 205 Y P N 
1554 J 56 F 31 100/72 187 203 Y N P 
1555 J 58 F 48 140/72 268 225 Y N N 
1556 J 61 F 36 170/92 235 219 Y P P 
1557 J 63 F 28 164/92 219 185 Y N P 
1558 J 62 F 35 130/180 67 161 N N N 
1559 J 61 M 30 150/68 137 189 Y N P 
1560 J 63 F 34 142/86 153 151 Y N P 
1561 J 69 F 27 120/164 140 136 N P P 
1562 J 63 M 26 140/92 167 205 Y P P 
1563 J 60 F 32 138/82 316 249 N N P 
1564 J 60 F 41 138/86 254 154 N N N 
1565 J 45 F 32 140/90 101 80 Y N N 
1566 J 66 F 36 130/68 142 221 Y P P 
1567 J 58 F 37 110/166 90 100 Y N N 
1568 J 63 M 29 130/74 222 152 Y N N 
1569 J 52 M 32 130/70 225 176 Y N N 
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Number Area Age Gender BMI BP FBS T-
choles. 
Family 
History 
rs12255372 rs7903146 
1570 J 63 F 26 130/70 207 227 Y P P 
1571 J 58 F 38 120/86 126 151 N N N 
1572 J 53 F 39 140/92 116 233 Y P N 
1573 J 64 F 32 110/76 132 180 N N P 
1574 J 49 F 27 126/78 176 229 Y N P 
1575 J 60 F 30 110/66 475 148 Y P N 
1576 J 62 F 33 144/96 196 185 Y N N 
1577 J 67 M 42 146/84 109 130 Y N N 
1578 J 52 M 25 110/76 161 102 Y N N 
1579 J 63 F 31 156/100 95 171 Y N N 
1580 J 50 M 37 142/100 144 214 Y N N 
1581 J 68 F 34 142/86 250 159 Y P N 
1582 J 78 M 30 132/88 149 185 Y P P 
1583 J 68 M 30 170/100 140 89 Y N N 
1584 J 45 F 28 130/80 119 179 N N P 
1585 J 51 M 25 140/82 123 117 Y P P 
1586 J 60 F 40 136/88 108 202 N N N 
1587 J 63 F 28 130/80 125 236 Y P P 
1588 J 76 F 46 130/70 126 176 Y P P 
1589 J 60 F 35 140/90 186 139 Y P P 
1590 J 60 F 27 120/72 112 132 Y N N 
1591 J 53 M 40 140/88 264 178 Y N N 
1592 J 72 M 26 160/80 124 177 N P N 
1593 J 42 F 39 126/74 81 187 Y N N 
1594 J 71 F 32 180/90 125 211 N N N 
1595 J 59 F 38 120/82 143 123 Y N N 
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Number Area Age Gender BMI BP FBS T-
Choles. 
Family 
History 
rs12255372 rs7903146 
1596 J 56 F 51 120/76 104 226 Y P N 
C1 D 44 M 25 110/84 85 176 N N N 
C2 D 36 F 22 122/81 87 150 N N N 
C3 D 40 M 26 115/75 90 180 N N N 
C4 D 44 M 24 118/86 79 161 N N N 
C5 D 42 F 25 112/78 82 161 N N N 
C6 D 45 F 23 118/84 88 145 N N N 
C7 D 47 F 23 110/77 81 150 N N N 
C8 D 45 F 26 124/82 85 148 N N P 
C9 D 41 F 26 116/80 89 155 N N N 
C10 D 37 F 27 120/81 92 165 N N N 
C11 D 32 F 26 90/60 60 156 N N N 
C12 D 45 M 27 120/80 88 166 N N N 
C13 D 61 M 34 140/90 74 129 N N N 
C14 D 32 F 27 110/80 70 156 N N N 
C15 D 73 F 34 126/62 91 147 N N N 
C16 D 37 F 24 110/70 87 140 N N N 
C17 D 32 F 22 100/60 84 150 N N N 
C18 D 50 F 27 110/70 90 156 N N N 
C19 D 51 F 22 108/70 86 170 N N N 
C20 D 48 F 21 110/60 85 160 N N N 
C21 D 34 M 25 128/77 85 194 N N N 
C22 D 36 M 24 120/80 85 173 N N N 
C23 D 37 F 23 109/76 80 139 N N N 
C24 D 49 M 29 129/79 85 152 N N N 
C25 D 39 F 25 113/75 86 145 N N N 
C26 D 41 F 24 111/71 99 192 N N N 
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Number Area Age Gender BMI BP FBS T-
Choles. 
Family 
History 
rs12255372 rs7903146 
C27 D 58 F 26 110/70 80 155 N N N 
C28 D 38 M 25 108/72 79 141 N N N 
C29 D 40 M 23 120/80 83 145 N N N 
C30 D 42 M 28 122/84 75 200 N N N 
C31 D 36 F 28 123/81 80 149 N N N 
C32 D 35 F 24 117/75 78 143 N N N 
C33 D 44 M 26 115/85 77 160 N N N 
C34 D 45 M 27 112/77 95 180 N N N 
C35 D 34 M 22 125/79 77 177 N N N 
C36 D 37 M 24 119/79 84 222 N N N 
C37 D 32 F 24 113/75 82 134 N N N 
C38 D 54 F 25 130/82 89 183 N N N 
C39 D 50 F 23 122/76 83 168 N N N 
C40 D 42 F 31 109/69 88 135 N P N 
C41 D 41 F 26 100/70 89 186 N N P 
C42 D 33 F 21 100/60 82 160 N N P 
C43 D 35 F 25 121/84 78 155 N N N 
C44 D 47 M 30 115/74 99 172 N N N 
C45 D 33 F 26 120/80 85 178 N N N 
C46 D 38 F 25 121/81 86 170 N N N 
C47 D 46 F 24 106/70 81 166 N N N 
C48 D 40 M 25 120/82 75 150 N N N 
C49 D 41 F 24 128/80 79 183 N N N 
C50 D 47 F 23 112/77 76 164 N N N 
C51 D 55 M 25 115/70 86 157 N N N 
C52 D 56 F 25 123/78 89 190 N N N 
C53 D 43 M 27 126/80 91 187 N N N 
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Number Area Age Gender BMI BP FBS T-
Choles. 
Family 
History 
rs12255372 rs7903146 
C54 D 42 M 28 105/74 93 167 N N N 
RF1 D 50 F 28 146/180 108 162 Y P P 
RF2 D 48 F 27 120/72 98 183 Y N N 
RF3 D 37 F 32 110/70 90 190 Y N N 
RF4 D 43 F 36 126/70 102 162 Y N N 
RF5 D 59 M 29 100/60 95 139 Y P P 
RF6 D 62 M 28 124/75 115 185 N P P 
RF7 D 41 F 30 120/80 100 175 Y N N 
RF8 D 48 M 23 120/80 75 163 Y P P 
RF9 D 43 F 22 115/70 80 180 Y N P 
RF10 D 34 F 24 110/80 88 179 Y P P 
RF11 D 53 F 37 160/100 91 165 Y N N 
RF12 D 36 M 29 120/65 77 188 Y N N 
RF13 D 33 F 32 127/71 77 171 Y P N 
RF14 D 45 M 30 125/87 88 183 Y N N 
RF15 D 39 F 26 125/88 90 210 Y N P 
RF16 D 42 M 30 115/70 110 190 Y N N 
RF17 D 37 F 28 117/73 102 178 Y N N 
RF18 D 38 F 29 105/94 92 153 Y N N 
RF19 D 36 F 23 105/76 83 180 Y N P 
RF20 D 49 F 35 142/64 85 213 Y N N 
RF21 D 39 F 30 124/78 92 200 Y N N 
RF22 D 56 F 32 130/85 90 199 Y N N 
RF23 D 40 M 29 146/90 123 196 Y N P 
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Number Area Age Gender BMI BP FBS T-
Choles. 
Family 
History 
rs12255372 rs7903146 
Q1 N 53 M 30 141/90 157 190 Y N N 
Q2 N 48 F 27 126/72 246 137 Y N N 
Q3 N 63 F 36 150/84 254 220 Y N N 
Q4 N 49 M 31 130/84 124 204 N N N 
Q5 N 55 F 34 130/84 161 121 N N N 
Q6 N 51 F 32 158/74 177 250 N N N 
Q7 N 55 F 30 140/90 118 161 Y N N 
Q8 N 53 M 31 130/82 110 209 Y N N 
Q9 N 61 F 31 150/86 112 209 N N N 
Q10 N 56 F 33 120/86 270 223 N N N 
Q11 N 62 F 31 120/82 217 183 Y N N 
Q12 N 67 F 46 142/95 135 190 Y N N 
Q13 N 58 F 36 151/96 142 138 Y N N 
Q14 N 43 M 28 111/83 320 247 Y N N 
Q15 N 56 F 35 130/82 102 70 N N N 
Q16 N 50 F 30 129/79 95 221 Y N N 
Q17 N 56 M 34 162/100 220 175 Y P P 
Q18 N 62 F 27 101/72 128 149 Y N N 
Q19 N 58 F 25 140/80 130 185 Y N N 
Q20 N 65 F 26 169/93 330 146 N P N 
Q21 N 61 F 32 165/90 107 132 Y N N 
Q22 N 66 M 41 130/80 94 172 Y N N 
Q23 N 66 M 32 152/70 158 250 Y N N 
Q24 N 49 F 36 144/88 140 91 N N N 
Q25 N 61 F 37 119/64 126 116 N N N 
Q26 N 58 M 29 140/96 122 233 Y N N 
Q27 N 51 F 32 136/82 184 136 Y N N 
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Number Area Age Gender BMI BP FBS T-
Choles. 
Family 
History 
rs12255372 rs7903146 
Q28 N 40 M 26 140/84 266 187 Y N N 
Q29 N 57 M 22 138/90 80 178 Y N N 
Q30 N 54 F 24 130/68 141 123 Y N N 
Q31 N 69 M 38 110/69 126 200 N N N 
Q32 N 70 F 39 125/74 217 162 Y N N 
Q33 N 58 F 32 127/70 78 188 N N N 
Q34 N 46 F 26 112/77 248 157 Y N N 
Q35 N 67 M 29 164/89 174 167 N N N 
Q36 N 36 F 25 104/70 293 155 Y N N 
Q37 N 40 F 19 125/82 217 152 Y P P 
Q38 N 42 F 21 133/85 205 205 N N N 
Q39 N 74 F 25 130/70 125 190 Y N N 
Q40 N 58 F 30 120/86 177 218 N P N 
Q41 N 39 M 24 142/92 131 160 Y N N 
Q42 N 76 F 40 110/77 185 201 N N N 
Q43 N 48 M 33 123/78 221 237 Y N P 
Q44 N 50 F 24 112/66 169 159 Y N N 
Q45 N 60 F 31 146/96 151 154 N N N 
Q46 N 47 F 37 147/83 169 202 Y N N 
Q47 N 51 M 34 156/101 116 156 N P N 
Q48 N 66 F 31 147/90 217 222 Y N N 
Q49 N 55 F 32 131/81 247 222 Y P N 
Q50 N 35 F 29 130/87 233 170 N P P 
Q51 N 60 F 22 107/78 171 239 N N N 
Q52 N 63 F 20 115/83 172 162 Y N P 
Q53 N 57 F 24 127/90 385 179 Y N N 
Q54 N 73 M 27 121/84 124 209 Y P N 
 
84 
 
Number Area Age Gender BMI BP FBS T-
Choles. 
Family 
History 
rs12255372 rs7903146 
Q55 N 61 F 26 134/88 468 221 N P P 
Q56 N 53 F 27 126/76 117 145 Y N P 
Q57 N 45 F 22 115/66 156 154 N P N 
Q58 N 41 M 23 140/85 111 240 Y P N 
Q59 N 52 M 22 144/82 230 172 Y N P 
Q60 N 65 M 25 137/81 118 189 N N N 
Q61 N 66 M 24 125/84 96 210 N N N 
Q62 N 63 M 24 130/70 160 222 Y N P 
Q64 N 63 M 25 130/75 174 155 Y N P 
Q65 N 55 M 25 111/69 153 199 N N N 
Q66 N 54 M 22 141/86 164 138 Y N N 
Q67 N 73 F 27 120/86 180 162 Y N N 
Q68 N 70 F 29 148/81 102 150 Y N N 
 
Table 4: Demographics and related information for the participants of this project. 
B: Bethlehem, R: Ramallah, J: Jerusalem, D: difference areas. C: normal control, RF: risk factors 
control. BMI: body mass index. FBS: fasting blood sugar, T.Choles.: total cholesterol.  
P and N are the results for positive and negative for the T-allele in cases and controls for the two 
mutations (rs7903146, rs12255372) 
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Questionnaire 
Project title: Detection of polymorphism in TF7L2 gene and association with type 2Diabetes 
mellitus 
 
Name and number, مقرلا/مسلأا:_____________________________________________ 
 
Age /  رمعلا :_____________________  Gender / سنجلا  :________________________ 
 
Weight / نزولا :___________________ Height /  لوطلا  :________________________ 
 
Family History /  ةلئاعلا خيرات   
Number of diabetic family members /   يركسلاب نيباصملا ةلئاعلا دارفأ :_________________ 
Relationship /  ةبارقلا ةلص:_______________________________________________ 
 
 
Clinical Tests / تاصوحفلا : 
Blood pressure /  مدلا طغض :________________________________________________ 
Fasting blood sugar /  مايصلا دعب ركسلا ةبسن :____________________________________ 
Total cholesterol / يلكلا لورتسيلوكلا :_________________________________________ 
Patient's consent /  ضيرملا ةقفاوم : 
 
 
I agree to participate in this study /  هذهب ةكراشملا ىلع قفاوأةساردلا  :__________________ 
